Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03547622 · ClinicalTrials.gov registry record · Early Phase 1
Galantamine and CBT4CBT Pilot to Prevent Relapse.
A Early Phase 1 study, sponsored by Yale University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 6
- Enrollment target
NCT03547622 is a Early Phase 1 study that has completed, run by Yale University. The registered enrollment target is 6 participants.
The verdict
NCT03547622, a Early Phase 1 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
The investigators are proposing a randomized pilot feasibility study to evaluate the effects of galantamine versus placebo on preventing relapse to opioid use following tapering from methadone or buprenorphine maintenance (Medication Assisted Treatment, or MAT) among adults with opioid use disorder, with additional behavioral therapy (web-based cognitive behavioral therapy) provided across all conditions to help individuals successfully transition from MAT to a drug-free state.
Interventions
- DRUG MAT taper with galantamine
- DRUG MAT taper with placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2018-05-01 |
| Est. Completion | 2019-02-28 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03547622
The ClinicalTrials.gov registry entry for NCT03547622 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which MAT taper with galantamine is the first listed.
NCT03547622 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03547622 about?
NCT03547622 is a clinical study titled "Galantamine and CBT4CBT Pilot to Prevent Relapse.". The investigators are proposing a randomized pilot feasibility study to evaluate the effects of galantamine versus placebo on preventing relapse to opioid use following tapering from methadone or buprenorphine maintenance (Medication Assisted Treatment, or MAT) among adults with opioid use disorder,...
What is the current status of trial NCT03547622?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 6 participants. The study started on 2018-05-01. Estimated completion is 2019-02-28.
What interventions are being tested in trial NCT03547622?
The interventions under investigation include: MAT taper with galantamine (DRUG), MAT taper with placebo (DRUG).
Who is sponsoring clinical trial NCT03547622?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.